The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Subscribe To Our Newsletter & Stay Updated
